As the never-ending battle with refractory gout continues, the need for more safe and effective treatments remains. Often, steady remission and target urate levels are not achieved with allopurinol alone.
A patient recently asked me, “What do you think it’s like to have RA” and “How would you describe it to someone you just met?” Could I walk a mile in her shoes? Here's my version and theirs.
Three European registries analyzed their cohorts for outcomes that may be related to seropositivity for anticitrullinated protein antibodies (ACPA), rheumatoid factor (RF) and anticarbamylated protein (anti-CarP) antibodies.
If you are responsible for the outcome and welfare of patients – you need prescribing rules.
If you are supervising others or responsible for the training of those learning rheumatology – you need prescribing rules.
Several rheumatoid arthritis studies have shown that tocilizumab (TCZ) may be as effective as monotherapy when compared to combination therapy (methotrexate plus TCZ), including the ACT-RAY, ACT-SURE and FUNCTION clinical trials.
A new Cochrane Review published today shows that targeting exercises to muscles that support and control the spine offers another strategy to reduce pain and disability caused by lower back pain.
Lower back pain is one of the most common health conditions worldwide. It can have substantial health and economic costs as people experience disability and general ill health, leading them to need time off work.
Widening experience with JAK inhibition for rheumatoid arthritis (RA) and tapering medications among RA patients in remission, along with the success of secukinumab for psoriatic arthritis (PsA), were the most important advances in rheumatology in 2015, according to specialists responding toMedPage Today.
SpA is a common disease, but with large variation in reported prevalence estimates, partly explained by differences in demographical and methodological characteristics.
Was 2015 a good year for psoriasis, IL-17, biosimilars, narcotics, the ACR and gout? Our year end review discusses the most impactful news and research from the last 12 months.
An administrative claims study of lupus patients drawn from the United States National Inpatient Sample between 2000 to 2011, studied hospitalization rates related to bacteremia, pneumonia, opportunistic fungal infection, herpes zoster, cytomegalovirus, or pneumocystis pneumonia (PCP).
A prospective study was conducted in Germany to establish predictors of 1 year survival after a hip fracture in elderly people.
The need for such study arose from the fact that patient outcomes remain disappointing within the first year after the fracture, regardless of advanced surgical care.
NEJM has published the results of two studies wherein IL-17 inhibition with secukinumab (SEC) was shown to be effective in patients with anklylosing spondylitis. (Citation source http://buff.ly/1VAndEl)
Although ankylosing spondylitis affects a predominantly male population, the ratio of men to women has declined from 9-10:1 in earlier studies to more recent estimates of 2-3:1 (F:M).
A nation-wide population based case-control study was conducted in Sweden, aimed at evaluating pregnancy outcomes in women with ankylosing spondylitis (AS).
I find it interesting that when the Q&A part of the lecture begins, everyone acts as if they just got on the elevator. Who is willing to go out on a limb and ask the first question? Is Q&A the best or worst part of lectures that you attend? What can you do change the impact of your next Q&A experience?
Last month, many rheumatologists offered up their favorite quotes. Most of these were on medicine, medical skills, some pertained to rheumatology and others were axioms for life.
Below are even more quotes from great rheumatologists.
Xavier Mariette, MD - Hôpitaux Universitaire Paris-Sud
